Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein

Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein

Author Ridker, Paul M. Google Scholar
Fonseca, Francisco A. H. Autor UNIFESP Google Scholar
Genest, Jacques Google Scholar
Gotto, Antonio M. Google Scholar
Kastelein, John J. P. Google Scholar
Khurmi, Nardev S. Google Scholar
Koenig, Wolfgang Google Scholar
Libby, Peter Google Scholar
Lorenzatti, Alberto J. Google Scholar
Nordestgaard, Borge G. Google Scholar
Shepherd, James Google Scholar
Willerson, James T. Google Scholar
Glynn, Robert J. Google Scholar
Grp, JTS Google Scholar
Institution Brigham & Womens Hosp
Universidade Federal de São Paulo (UNIFESP)
McGill Univ
Cornell Univ
Univ Amsterdam
Astra Zeneca
Univ Ulm
Hosp Cordoba
Herlev Univ Hosp
Univ Glasgow
St Lukes Episcopal Hosp
Abstract The Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) is a randomized, double-blind, placebo-controlled primary prevention trial of statin therapy among persons with average to low levels of low-density lipoprotein (LDL) cholesterol who are at increased cardiovascular risk due to elevated plasma concentrations of the inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP). A total of 17,802 persons with LDL cholesterol <130 mg/dl (3.36 mmol/L) and hs-CRP >= 2 mg/L were recruited from 26 countries and randomly allocated to 20 mg/day rosuvastatin or placebo. in contrast to previous studies of statin therapy in primary prevention, JUPITER is evaluating a group with modest plasma concentrations of LDL cholesterol (median 108 mg/dl, interquartile range 94 to 119). Further, the trial includes 6,801 women (38.2%) and 5,577 participants with metabolic syndrome (32.1%). Thus, in addition to broadening our understanding of statin therapy and inflammation, the JUPITER trial will provide important and clinically relevant information on primary prevention among patients who do not currently qualify for lipid-lowering therapy. in conclusion, as 20 mg of rosuvastatin can reduce LDL cholesterol by up to 50%, JUPITER will also provide crucial safety data for several thousand patients who should achieve LDL cholesterol levels <50 mg/dl on a long-term basis. (c) 2007 Elsevier Inc. All rights reserved.
Language English
Date 2007-12-01
Published in American Journal of Cardiology. Bridgewater: Excerpta Medica Inc-Elsevier B.V., v. 100, n. 11, p. 1659-1664, 2007.
ISSN 0002-9149 (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 1659-1664
Origin http://dx.doi.org/10.1016/j.amjcard.2007.09.072
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000251567400011
URI http://repositorio.unifesp.br/handle/11600/30156

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account